Wound contraction inhibitor

Details Wound contraction inhibitor Wound contraction inhibitor

2006-01-10

2006-01-10

Tate, Christopher R. (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S012200, C530S324000

Reexamination Certificate

active

06984621

ABSTRACT:
The pharmaceutical formulation for inhibiting wound contraction of the present invention includes secretory leukocyte protease inhibitor as an active ingredient. The SLPI concentration in the pharmaceutical formulation is preferably 1–5000 ng/ml, and more preferably 1–100 ng/ml. The pharmaceutical formulation for inhibiting wound contraction of the present invention may be prepared as an external preparation including a base and the SLPI as an active ingredient. The pharmaceutical formulation for inhibiting wound contraction of the present invention may be prepared as an injection including the SLPI as an active ingredient. The external preparation may preferably include a preservative. The injection may preferably include a stabilizer (an antioxidant), a preservative and an analgesic agent.

REFERENCES:
patent: 5376633 (1994-12-01), Lezdey et al.
patent: 5532215 (1996-07-01), Lezdey et al.
patent: 5633227 (1997-05-01), Muller et al.
patent: 5780440 (1998-07-01), Lezdey et al.
patent: 5871956 (1999-02-01), Bandyopadhyay et al.
patent: 6017880 (2000-01-01), Eisenberg et al.
patent: 6610748 (2003-08-01), Yabuta et al.
patent: WO 92/06706 (1992-04-01), None
patent: WO 96/08275 (1996-03-01), None
patent: WP 99/17800 (1999-04-01), None
patent: WO 9943352 (1999-09-01), None
Stetler et al., “Secretion of Active, Full- and Half-Length Human Secretory Leukocyte Protease Inhibitor by Saccharomyces cerevisiae,” (1989) Bio/Technology, 7(1), 55-60.
Eisenberg et al., “Location of the Protease-inhibitory Region of Secretory Leukocyte Protease Inhibitor” (May 15, 1990) The Journal of Biological Chemistry, 265(14), 7976-7981.
McNeeley et al., “Secretory Leukocyte Protease Inhibitor: A Human Saliva Protein Exhibiting Anti-Human Immunodeficiency Virus 1 Activity In Vitro” (Jul. 1995) The Journal of Clinical Investigation, 96, 456-464.
Thompson et al., “Isolation, Properties and Complete Amino Acid Sequence of Human Secretory Leukocyte Protease Inhibitor, A Potent Inhibitor or Leukocyte Elastase” (Sep. 15, 1986) Proc. Natl. Acad. Sci. USA, 83(18), 6692-6696.
Lucey et al., “Recombinant Human Secretory Leukocyte-Protease Inhibitor: In Vitro Properties, and Amelioration of Human Neutrophil Elastase-Induced Emphysema and Secretory Cell Metaplasia in the Hamster” (1990) J. Lab. Clin. Med., 115(2), 224-232.
Ohlsson et al., “Structure, Genomic Organization, and Tissue Distribution of Human Secretory Leukocyte-Protease Inhibitor (SLPI): A Potent Inhibitor of Neutrophil Elastase” (1986) Pulmonary Emphysema and Proteolysis, Academic Press, Inc., pp. 307-324.
Sumi, Yukio et al., “Secretory Leukocyte Protease Inhibitor is a Novel Inhibitor of Fibroblast-medicated Collagen Gel Contraction,”Experimental Cell Research, vol. 256, No. 1, Apr. 10, 2000, pp. 203-212.
Ashcroft, Gillian S. et al., “Secretory Leukocyte Protease Inhibitor Mediates Non-redundant Functions Necessary for Normal Wound Healing,”Nature Medicine, vol. 6, No. 10, Oct. 2000, pp. 1147-1153.
Wingens, Miriam et al., “Induction of SLPI (ALP/HUSI-I) in Epidermal Keratinocytes,”The Journal of Investigative Dermatology, vol. 111, No. 6, Dec. 1998, pp. 996-1002.

Affiliated with

Also associated with

Rating

Wound contraction inhibitor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Wound contraction inhibitor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Wound contraction inhibitor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3600222